SCHEMBL14740649

SCHEMBL14740649

Nc1ccc(-c2coc3cc(OS(=O)(=O)C(F)(F)F)ccc3c2=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.64
MAPT P10636 6/20 0.53
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
KDM4E B2RXH2 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
TP53 P04637 3/20 0.53
CYP3A4 P08684 3/20 0.53
HPGD P15428 3/20 0.53
XDH P47989 1/20 0.51
HDAC6 Q9UBN7 3/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
MAPK1 P28482 1/20 0.50
STAT1 P42224 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18872545 0.93 STS (0.66) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL16372524 0.89 STS (0.76) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL15237453 0.86 STS (0.63) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL14740635 0.84 STS (0.56) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL14740689 0.84 ALDH2 (0.61) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL17718166 0.78 STS (0.57) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL17718161 0.78 STS (0.57) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL1500042 0.78 STS (0.49) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL3355210 0.78 STS (0.65) STSMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL17718209 0.77 STS (0.56) STSMAPTALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751090-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION Gilead Sciences, Inc. (US) 2014-07-09 EP disclosed
US-8673966-B2 ALDH-2 inhibitors in the treatment of addiction GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20130231325-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION GILEAD SCIENCES. INC. (US) 2013-09-05 US disclosed
WO-2013033377-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION GILEAD SCIENCES, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231325-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH1B1 STS 832/4885MAPT 1343/4885ALDH1A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.